ALIKO Stock Overview
A cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Ikonisys S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.44 |
| 52 Week High | €1.80 |
| 52 Week Low | €1.23 |
| Beta | 0.70 |
| 11 Month Change | -8.28% |
| 3 Month Change | -2.70% |
| 1 Year Change | 3.60% |
| 33 Year Change | -46.67% |
| 5 Year Change | n/a |
| Change since IPO | -63.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALIKO | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | -2.7% | 5.0% | 1.2% |
| 1Y | 3.6% | 27.2% | 0.8% |
Return vs Industry: ALIKO underperformed the French Medical Equipment industry which returned 27.2% over the past year.
Return vs Market: ALIKO exceeded the French Market which returned 0.8% over the past year.
Price Volatility
| ALIKO volatility | |
|---|---|
| ALIKO Average Weekly Movement | 3.2% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.1% |
Stable Share Price: ALIKO has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ALIKO's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 10 | Mario Crovetto | ikonisys.com |
Ikonisys S.A., a cell-based diagnostics company, develops, produces, and markets medical diagnostic products for early and accurate detection of cancer diseases in the United States and Europe. It offers Ikoniscope Robotic Microscopes, including Ikoniscope20 that provides automated slide handling, slide scanning, and real-time image capture and analysis; and Ikoniscope20max that automates the fluorescence microscopy solution. The company also provides oncoFISH bladder that allows scanning and analysis of cells from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of gene rearrangements commonly associated with non-small cell lung carcinoma; oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene, which is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems.
Ikonisys S.A. Fundamentals Summary
| ALIKO fundamental statistics | |
|---|---|
| Market cap | €16.70m |
| Earnings (TTM) | -€2.70m |
| Revenue (TTM) | €617.19k |
26.0x
P/S Ratio-5.9x
P/E RatioIs ALIKO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALIKO income statement (TTM) | |
|---|---|
| Revenue | €617.19k |
| Cost of Revenue | €280.18k |
| Gross Profit | €337.01k |
| Other Expenses | €3.04m |
| Earnings | -€2.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 54.60% |
| Net Profit Margin | -437.39% |
| Debt/Equity Ratio | 21.6% |
How did ALIKO perform over the long term?
See historical performance and comparison